Results 21 to 30 of about 6,542,588 (257)

Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan

Drug Design, Development and Therapy
Bradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS, Blair J, Horikawa R, Linglart A, Yuen KC   +4 more
doaj   +1 more source

Growth hormone use in pediatric growth hormone deficiency and other pediatric growth disorders.

The American journal of managed care, 2000
The diagnosis and management of growth disorders in children, particularly disorders that respond to therapy with growth hormone (GH), raise challenging clinical and economic issues. Several such issues are presented in the following article in which Dr. Ron Rosenfeld examines the evaluation and diagnosis of the child with short stature; Dr.
R, Rosenfeld, D B, Allen, M H, MacGillivray, C, Alter, P, Saenger, H, Anhalt, R, Hintz, H P, Katz   +7 more
core   +3 more sources

Cost-effectiveness of a connected injection device for daily somatropin therapy in pediatric growth hormone deficiency in Spain: a scenario-based microsimulation analysis using real-world data [PDF]

Journal of Comparative Effectiveness Research
Aim: Growth hormone deficiency (GHD) in pediatric patients is characterized by impaired growth and reduced quality of life. Recombinant human growth hormone therapy requires consistent daily administration, yet adherence remains challenging. Electronic
Antonio de Arriba, Claudia Roeder, Emilia Nivelle, Paula van Dommelen, Jose J Alcon Saez, Cristina Latre Gorbe, Heidi de los Santos Real, Irene Sánchez-Collado, Falko Boehm, Cristina Masseria   +9 more
doaj   +2 more sources

Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)

Biologics: Targets & Therapy, 2008
Dana S HardinOhio State University and Columbus Children’s Hospital, Columbus, Ohio, USAAbstract: Somatotropin (growth hormone, GH) of recombinant DNA origin has provided a readily available and safe drug that has greatly improved management of
Dana S Hardin
doaj   +1 more source

Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited. [PDF]

J Endocr Soc, 2021
Yau M, Rapaport R.
europepmc   +3 more sources

Economic burden of growth hormone deficiency in a US pediatric population [PDF]

Journal of Managed Care & Specialty Pharmacy, 2021
Abstract Pediatric GHD is a rare disorder of short stature that is currently treated with daily injections of GH. In addition to short stature, GHD is associated with other comorbidities such as impaired musculoskeletal development, cardiovascular disease, and decreased quality of life.
Kaplowitz, Paul B, Manjelievskaia, Janna, Lopez-Gonzalez, Lorena, Marrow, Cynthia D, Pitukcheewanont, Pisit, Smith, Alden   +5 more
openaire   +3 more sources

Can long-acting growth hormone improve adherence in pediatric growth hormone deficiency? [PDF]

Endocrine
Abstract Growth hormone deficiency (GHD) in childhood and adolescence requires long-term therapy with recombinant human growth hormone (rhGH). Although daily injections are highly effective, they impose a considerable treatment burden that often leads to suboptimal adherence and compromised growth outcomes.
Rodaro C, Tamaro G, Fachin A, Nicolardi F, Tommasi S, Tornese G.   +5 more
europepmc   +5 more sources

What do we do now that the long-acting growth hormone is here?

Frontiers in Endocrinology, 2022
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj   +1 more source

The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency [PDF]

Translational Pediatrics, 2021
Recombinant human growth hormone (rhGH) was approved for the therapy of pediatric patients with growth hormone deficiency (GHD) by the Food and Drug Administration (FDA) of the United States in 1985. This study aims to evaluate the effects of rhGH therapy on thyroid function in pediatric patients with GHD.A total of 55 pediatric patients, who had been ...
Yao, Qian, Zheng, Dong, Liang, Yan, Hou, Ling, Ying, Yan-Qin, Luo, Xiao-Ping, Wu, Wei   +6 more
openaire   +2 more sources

Should Pediatric Endocrinologists Consider More Carefully When to Perform a Stimulation Test?

Frontiers in Endocrinology, 2021
IntroductionPediatric endocrinology rely greatly on hormone stimulation tests which demand time, money and effort. The knowledge of the pattern of pediatric endocrinology stimulation tests is therefore crucial to optimize resources and guide public ...
Arturo Penco, Benedetta Bossini, Manuela Giangreco, Viviana Vidonis, Giada Vittori, Nicoletta Grassi, Maria Chiara Pellegrin, Elena Faleschini, Egidio Barbi, Egidio Barbi, Gianluca Tornese   +10 more
doaj   +1 more source